A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus

A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus

Abstract The Food and Drug Administration (FDA) has approved vaccines designed by GSK, Pfizer and Moderna to protect high-risk populations against respiratory syncytial virus (RSV). These vaccines employ the pre-fusion F (pre-F) protein as the immunogen. In this study, we explored an mRNA vaccine ba...

Full description

Saved in:
Bibliographic Details
Main Authors: Min Lin, Yifan Yin, Xiaomeng Zhao, Chen Wang, Xueqing Zhu, Letao Zhan, Li Chen, Siling Wang, Xue Lin, Jun Zhang, Ningshao Xia, Zizheng Zheng
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-56302-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items